Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 86.19 USD 0.48% Market Closed
Market Cap: 50B USD

Edwards Lifesciences Corp
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Edwards Lifesciences Corp
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Edwards Lifesciences Corp
NYSE:EW
Net Issuance of Common Stock
-$782.5m
CAGR 3-Years
1%
CAGR 5-Years
-10%
CAGR 10-Years
-26%
Boston Scientific Corp
NYSE:BSX
Net Issuance of Common Stock
$290m
CAGR 3-Years
32%
CAGR 5-Years
-32%
CAGR 10-Years
11%
Stryker Corp
NYSE:SYK
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Net Issuance of Common Stock
-$490m
CAGR 3-Years
50%
CAGR 5-Years
0%
CAGR 10-Years
6%
IDEXX Laboratories Inc
NASDAQ:IDXX
Net Issuance of Common Stock
-$1.1B
CAGR 3-Years
-6%
CAGR 5-Years
-33%
CAGR 10-Years
-10%
Intuitive Surgical Inc
NASDAQ:ISRG
Net Issuance of Common Stock
-$1.8B
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Edwards Lifesciences Corp
Glance View

Nestled at the intersection of medical innovation and patient care, Edwards Lifesciences Corp. has long been a pioneer in the field of heart disease solutions. Emerging from its origins in the 1950s, the company has consistently focused on advancing heart valve technology, a critical area given the prevalence and severity of cardiovascular diseases. Their journey began with the development of the first artificial heart valve, setting a foundation of innovation that continues to propel the company forward. Today, Edwards is renowned for its leadership in transcatheter aortic valve replacement (TAVR) technology, an area that revolutionizes the treatment of aortic stenosis, a condition that narrows heart valves and impedes blood flow. This shift from open-heart surgeries to less invasive procedures, facilitated by Edwards' products, has marked a significant turning point in patient care, minimizing recovery times and enhancing patient outcomes. Financially, Edwards Lifesciences thrives on a robust business model centered around its technologically advanced heart valve systems and critical care technologies. The company operates through a direct sales force as well as strategic partnerships, ensuring their devices reach hospitals and healthcare providers globally. Their commitment to research and development ensures a steady pipeline of innovative products, which not only differentiates them in the market but also drives their profitability. Revenue streams are primarily fueled by the sales of their TAVR systems, surgical heart valves, and monitoring technologies—each designed to meet the complex and evolving needs of patients with structural heart diseases. By continually investing in cutting-edge technology and expanding their global reach, Edwards Lifesciences not only supports its bottom line but also positions itself as a leader in the transformative field of medical device innovation.

EW Intrinsic Value
59.15 USD
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Edwards Lifesciences Corp's Net Issuance of Common Stock?
Net Issuance of Common Stock
-782.5m USD

Based on the financial report for Sep 30, 2025, Edwards Lifesciences Corp's Net Issuance of Common Stock amounts to -782.5m USD.

What is Edwards Lifesciences Corp's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
-26%

Over the last year, the Net Issuance of Common Stock growth was 41%. The average annual Net Issuance of Common Stock growth rates for Edwards Lifesciences Corp have been 1% over the past three years , -10% over the past five years , and -26% over the past ten years .

Back to Top